BioMS Medical Release: European Journal Of Neurology Publishes MBP8298 Phase II And Long-Term Follow-up Data

EDMONTON, Alberta, June 13 /PRNewswire/ -- BioMS Medical Corp (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced that results of the phase II and long-term follow-up treatment of MS patients with MBP8298 have been published in the European Journal of Neurology (EJN). The publication highlights long-term efficacy, safety and mechanism of action data in respect of MBP8298. The journal also features an editorial entitled “The coming of age for antigen-specific therapy of multiple sclerosis.” The data was published in the EJN online early issue and is expected to appear in the August 2006 printed issue.

MORE ON THIS TOPIC